Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Esperion ( (ESPR) ) has shared an update.
On April 2, 2026, Esperion Therapeutics amended its existing credit agreement to add a $25 million term loan, resetting call protection terms that impose make-whole and stepped prepayment premiums for up to four years. On the same date, the company also sold up to $100 million of future royalty and milestone receivables tied to Bempedoic Acid and other licensed products in the Otsuka territory for an upfront payment of $50 million, providing additional non-dilutive financing.
These financings helped support Esperion’s April 2 closing of its previously announced acquisition of Corstasis Therapeutics, following a March 2, 2026 merger agreement that valued upfront cash consideration at $75 million plus up to $180 million in milestones and future royalty-based payments. By acquiring Corstasis and its FDA-approved nasal spray loop diuretic Enbumyst, cleared in September 2025 for edema associated with heart failure and hepatic and renal disease in adults, Esperion expands its cardiovascular franchise into an acute-adjacent outpatient setting and aims to leverage its existing commercial infrastructure to drive portfolio diversification and sustained revenue growth.
The most recent analyst rating on (ESPR) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
Spark’s Take on ESPR Stock
According to Spark, TipRanks’ AI Analyst, ESPR is a Neutral.
The score is held back primarily by weak financial structure and cash generation (negative equity, ongoing net losses, and negative free cash flow). Technicals also suggest a softer trend (below key moving averages with negative MACD). These are partly offset by a more constructive earnings-call outlook featuring strong commercial growth and clearer 2026 planning, but the lack of earnings-based valuation support (negative P/E, no dividend) limits the overall rating.
To see Spark’s full report on ESPR stock, click here.
More about Esperion
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily non-statin drugs for lowering LDL cholesterol and a nasal spray loop diuretic for edema tied to congestive heart failure and hepatic and renal disease, leveraging a broad U.S. commercial infrastructure and global approvals in more than 40 countries.
The company emphasizes expertise in ACLY biology to develop and commercialize transformative medicines worldwide. It positions itself as a partner-of-choice for innovators seeking U.S. market access through acquisitions, in-licensing, co-promotion and revenue-sharing, while advancing a pipeline that includes candidates for primary sclerosing cholangitis and renal diseases.
Average Trading Volume: 4,975,650
Technical Sentiment Signal: Hold
Current Market Cap: $670.3M
For detailed information about ESPR stock, go to TipRanks’ Stock Analysis page.